[
  {
    "ts": null,
    "headline": "Lilly Sues U.S. to Change Hospital Drug Discount Payments",
    "summary": "Lilly Sues U.S. to Change Hospital Drug Discount Payments",
    "url": "https://finnhub.io/api/news?id=1fdc08e86973138937444bbdc5c20dff4590c2edce8ce63e628929fab6e9c8a7",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731691440,
      "headline": "Lilly Sues U.S. to Change Hospital Drug Discount Payments",
      "id": 131413484,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Lilly Sues U.S. to Change Hospital Drug Discount Payments",
      "url": "https://finnhub.io/api/news?id=1fdc08e86973138937444bbdc5c20dff4590c2edce8ce63e628929fab6e9c8a7"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Vaccine Stocks Fall on RFK Jr. HHS Nomination; GM Plans to Cut 1,000 Salaried Workers",
    "summary": "Top Midday Stories: Vaccine Stocks Fall on RFK Jr. HHS Nomination; GM Plans to Cut 1,000 Salaried Workers",
    "url": "https://finnhub.io/api/news?id=8412088439c0646b183323f47845df452cdcfe2cff42a84fb647b9ae4c34e77e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731690445,
      "headline": "Top Midday Stories: Vaccine Stocks Fall on RFK Jr. HHS Nomination; GM Plans to Cut 1,000 Salaried Workers",
      "id": 131375238,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Top Midday Stories: Vaccine Stocks Fall on RFK Jr. HHS Nomination; GM Plans to Cut 1,000 Salaried Workers",
      "url": "https://finnhub.io/api/news?id=8412088439c0646b183323f47845df452cdcfe2cff42a84fb647b9ae4c34e77e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=de2a9d3dbccffd63546ac9f13c3f225c27e0f2872d292a07296915d81b424957",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731688380,
      "headline": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "id": 131413507,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=de2a9d3dbccffd63546ac9f13c3f225c27e0f2872d292a07296915d81b424957"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too",
    "summary": "Donald Trump’s nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services is sending shockwaves throughout the broader pharma industry, beyond vaccine makers such as Moderna and Pfizer.  One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic.  Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such drugs and are conducting studies to show that the benefits extend beyond weight loss to conditions such as cardiovascular disease and sleep apnea.",
    "url": "https://finnhub.io/api/news?id=aaae1ad0a587180c6c3ff09b1ceae052ea6a9dae247030a61b8a37cc38fee28e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731681261,
      "headline": "Heard on the Street: RFK Jr. Is Spooking Obesity Investors Too",
      "id": 131373348,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Donald Trump’s nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services is sending shockwaves throughout the broader pharma industry, beyond vaccine makers such as Moderna and Pfizer.  One area of heightened focus is the fast-growing market for obesity and diabetes drugs like Mounjaro and Ozempic.  Eli Lilly and Novo Nordisk are seeking to broaden insurance coverage for such drugs and are conducting studies to show that the benefits extend beyond weight loss to conditions such as cardiovascular disease and sleep apnea.",
      "url": "https://finnhub.io/api/news?id=aaae1ad0a587180c6c3ff09b1ceae052ea6a9dae247030a61b8a37cc38fee28e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
    "summary": "The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.",
    "url": "https://finnhub.io/api/news?id=1350f1a765898814cfdafda3a8ff5af9fde1eb04128938c4481e9bf7fc7b9a03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731679440,
      "headline": "Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe",
      "id": 131375206,
      "image": "https://media.zenfs.com/en/zacks.com/7d0183f93b51892d562cc8047433f507",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.",
      "url": "https://finnhub.io/api/news?id=1350f1a765898814cfdafda3a8ff5af9fde1eb04128938c4481e9bf7fc7b9a03"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program",
    "summary": "Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.",
    "url": "https://finnhub.io/api/news?id=3e7b0631b7e92536cb51cb07fad9301912060ffea2d0b18a3cb8a9c81667c812",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731679333,
      "headline": "Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program",
      "id": 131375244,
      "image": "https://www.investopedia.com/thmb/vsYG-gCJGNtOiilNTZfgwn2tJns=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2183999853-a2fffbde988c49b0a85ced3313519efb.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facilities.",
      "url": "https://finnhub.io/api/news?id=3e7b0631b7e92536cb51cb07fad9301912060ffea2d0b18a3cb8a9c81667c812"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
    "summary": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
    "url": "https://finnhub.io/api/news?id=93040c381fb1948956a55076fd4483e8a980b1b110b6272cf1876c06b7c38516",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731678501,
      "headline": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
      "id": 131413508,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.",
      "url": "https://finnhub.io/api/news?id=93040c381fb1948956a55076fd4483e8a980b1b110b6272cf1876c06b7c38516"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr. News Hits Global Pharma Stocks",
    "summary": "President-elect Donald Trump's selection of vaccine skeptic Robert F. Kennedy Jr. as health secretary weighed on global pharmaceutical stocks Friday.    In Europe, shares in Bavarian Nordic fell more than 16%.",
    "url": "https://finnhub.io/api/news?id=b979e934f34b2c40cfe6bbbdbfc7e5edb3d3cd5f1d65d49b2c413a950bb9d783",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731671155,
      "headline": "RFK Jr. News Hits Global Pharma Stocks",
      "id": 131373353,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President-elect Donald Trump's selection of vaccine skeptic Robert F. Kennedy Jr. as health secretary weighed on global pharmaceutical stocks Friday.    In Europe, shares in Bavarian Nordic fell more than 16%.",
      "url": "https://finnhub.io/api/news?id=b979e934f34b2c40cfe6bbbdbfc7e5edb3d3cd5f1d65d49b2c413a950bb9d783"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare stocks head for worst week since 2020 as put volumes soar",
    "summary": "Healthcare stocks head for worst week since 2020 as put volumes soar",
    "url": "https://finnhub.io/api/news?id=a6c99f5a83eb616b0f8df1626e37719ba0919783994aba3050a5ad15c743f098",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731668135,
      "headline": "Healthcare stocks head for worst week since 2020 as put volumes soar",
      "id": 131413509,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Healthcare stocks head for worst week since 2020 as put volumes soar",
      "url": "https://finnhub.io/api/news?id=a6c99f5a83eb616b0f8df1626e37719ba0919783994aba3050a5ad15c743f098"
    }
  },
  {
    "ts": null,
    "headline": "Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?",
    "summary": "Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times.  It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed off-label for weight control, and Zepbound, specifically approved for the weight control indication.  Lilly and its big pharma rival Novo Nordisk today dominate the weight loss drug market, but competition may be on the horizon.",
    "url": "https://finnhub.io/api/news?id=2a660b956aa6ed7bffb8e9ad15522abae55fb2bc81cab50f3f370994ce67647e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731661500,
      "headline": "Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?",
      "id": 131365689,
      "image": "https://g.foolcdn.com/editorial/images/797672/gettyimages-woman-points-at-computer-with-a-pen-to-show-something-to-a-colleague.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has helped its earnings and its stock soar in recent times.  It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed off-label for weight control, and Zepbound, specifically approved for the weight control indication.  Lilly and its big pharma rival Novo Nordisk today dominate the weight loss drug market, but competition may be on the horizon.",
      "url": "https://finnhub.io/api/news?id=2a660b956aa6ed7bffb8e9ad15522abae55fb2bc81cab50f3f370994ce67647e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: sues US federal agency",
    "summary": "Eli Lilly has sued the HRSA for rejecting its plan to modify the 340B program, aimed at offering reduced prices on its drugs via a more efficient cash replenishment model, in partnership with...",
    "url": "https://finnhub.io/api/news?id=5fb7afdcc1f405699c23447e510965b2d7dd651c5b78ea47c10a0c8496bd9527",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731654495,
      "headline": "Eli Lilly: sues US federal agency",
      "id": 131368094,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has sued the HRSA for rejecting its plan to modify the 340B program, aimed at offering reduced prices on its drugs via a more efficient cash replenishment model, in partnership with...",
      "url": "https://finnhub.io/api/news?id=5fb7afdcc1f405699c23447e510965b2d7dd651c5b78ea47c10a0c8496bd9527"
    }
  },
  {
    "ts": null,
    "headline": "Lilly sues US agency over blocking of drug-rebate program",
    "summary": "The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income populations.  Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid.  Eli Lilly said its program is designed to pay cash directly to 340B covered entities every week, ensuring they pay no more than the 340B ceiling price.",
    "url": "https://finnhub.io/api/news?id=7c909d90665cb8eeafef530a7ad6a777255100c8680cd6bbebcf855eb2718a23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731647112,
      "headline": "Lilly sues US agency over blocking of drug-rebate program",
      "id": 131365693,
      "image": "https://media.zenfs.com/en/reuters.com/a0b3f74ab51b05903c71462fa4d1a21d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income populations.  Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid.  Eli Lilly said its program is designed to pay cash directly to 340B covered entities every week, ensuring they pay no more than the 340B ceiling price.",
      "url": "https://finnhub.io/api/news?id=7c909d90665cb8eeafef530a7ad6a777255100c8680cd6bbebcf855eb2718a23"
    }
  },
  {
    "ts": null,
    "headline": "Lilly sues US agency over block on its drug-rebate program",
    "summary": "The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income populations.  Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid.  Eli Lilly said its program is designed to pay cash directly to 340B covered entities every week, ensuring they pay no more than the 340B ceiling price.",
    "url": "https://finnhub.io/api/news?id=f27f5e5832ab9e05764975d58c948120065ade5630ef13d5777ba35b67b27871",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731647112,
      "headline": "Lilly sues US agency over block on its drug-rebate program",
      "id": 131365691,
      "image": "https://media.zenfs.com/en/reuters-finance.com/a0b3f74ab51b05903c71462fa4d1a21d",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that serve low-income populations.  Drugmakers must participate in the program to receive funds from government health insurance programs like Medicare and Medicaid.  Eli Lilly said its program is designed to pay cash directly to 340B covered entities every week, ensuring they pay no more than the 340B ceiling price.",
      "url": "https://finnhub.io/api/news?id=f27f5e5832ab9e05764975d58c948120065ade5630ef13d5777ba35b67b27871"
    }
  }
]